Its levels have been found to be reduced in patients with NAFLD/MASLD and obesity, with data suggesting that hepatic insulin resistance may influence IGF-I levels through modulation of growth hormone-stimulated hepatic synthesis of IGF-I [37,60]. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.